27 April 2023 - trading update
The AIM-listed infection prevention and control company has issued a trading update for the year to 31 March 2023 and this has confirmed that trading was in line with expectations. Revenues for the year are expected to be £4.6m with an adjusted EBITDA loss of £0.8m. Cash at the year end was £0.7m. In the current financial year the company expects significant growth and a return to profitability, but we suggest that subscribers wait for the publication of the audited results in August before investing. HOLD . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
